Skip to main content

Table 2 Characteristics of IPD patients by age and immunocompromised status (n = 281)

From: Invasive pneumococcal disease among adults in Japan, April 2013 to March 2015: disease characteristics and serotype distribution

  Group 1 n = 10 (15–39 years, Nonimmunocompromised) Group 2 n = 48 (40–64 years Nonimmunocompromised) Group 3 n = 116 (> = 65 years, Nonimmunocompromised) Group 4 n = 107 (> = 15 years Immunocompromised)
Variable n/Na (%) n/Na (%) n/Na (%) n/Na (%)
Female 3/10 (30) 10/48 (21) 46/116 (40) 44/107 (41)
BMI
 Normal or Healthy Weight (18.5 – 24.9) 5/7 (71) 24/42 (57) 57/95 (60) 47/97 (48)
 Overweight (25.0 and Above) 0/7 (0) 11/42 (26) 12/95 (13) 17/97 (18)
 Underweight (Below 18.5) 2/7 (29) 7/42 (17) 26/95 (27) 33/97 (34)
Smoking history 5/9 (56) 26/44 (59) 49/100 (49) 48/95 (51)
Alcohol abuse 2/9 (22) 13/43 (30) 13/103 (13) 11/95 (12)
Preceding influenza 0/4 (0) 2/34 (6) 8/83 (10) 1/66 (2)
Vaccination history of PPSV23 0/8 (0) 1/40 (3) 6/91 (7) 9/85 (11)
Comorbidities 1/10 (10) 25/48 (52) 69/116 (59) 107/107 (100)
Clinical presentation
 Bacteremia without any focus 1/10 (10) 4/48 (8) 12/116 (10) 29/107 (27)
 Meningitis 3/10 (30) 9/48 (19) 18/116 (16) 14/107 (13)
 Bacteremic pneumonia 6/10 (60) 27/48 (56) 80/116 (69) 54/107 (50)
 Othersb 0/10 (10) 8/48 (17) 6/116 (5) 10/107 (9)
Outcomec
 Fatal 0/10 (0) 6/48 (13) 18/116 (16) 31/107 (29)
Serotype
 PCV13 type 4/10 (40) 27/48 (56) 65/116 (56) 34/107 (32)
 PPSV23 type 7/10 (70) 38/48 (79) 85/116 (73) 55/107 (51)
  1. BMI Body mass index, PPSV23 23-valent pneumococcal polysaccharide vaccine
  2. a Number of available answers
  3. b Others included bacteremic arthritis, bacteremic cellulitis, bacteremic spondylitis bacteremic cholangitis, bacteremic empyema, infected aortic aneurysm and infective endocarditis
  4. c The case fatality was defined as reporting of death by the case-reporting form at the time of reporting